Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Beam Therapeutics Inc.

Market Cap 3.3B 2.9B 2.68B 2.5B 4.69B 313B 4.77B 32.12B 12.43B 154B 12.41B 12.14B 534B P/E 2026 *
-7.57x
P/E 2027 * -7.25x
Enterprise Value 2.45B 2.15B 1.98B 1.86B 3.48B 232B 3.54B 23.81B 9.22B 114B 9.2B 9B 396B EV / Sales 2026 *
33.5x
EV / Sales 2027 * 24.4x
Free-Float
98.64%
Yield 2026 *
-
Yield 2027 * -
1 day+3.83%
1 week+5.57%
Current month+4.13%
1 month+15.11%
3 months+43.17%
6 months+21.86%
Current year+23.70%
1 week 32.66
Extreme 32.66
36.88
1 month 28.3
Extreme 28.3
36.88
Current year 21.63
Extreme 21.63
36.88
1 year 15.6
Extreme 15.6
36.88
3 years 13.52
Extreme 13.525
49.5
5 years 13.52
Extreme 13.525
138.52
10 years 13
Extreme 13
138.52
Manager TitleAgeSince
Chief Executive Officer 48 2016-12-31
President 57 2020-01-23
Director of Finance/CFO 48 2024-12-18
Director TitleAgeSince
Director/Board Member 48 2016-12-31
Director/Board Member 75 2018-04-30
Director/Board Member 56 2019-10-09
Date Insider Type Main position Quantity % Market Cap.
06-16Fiscal year

Chairperson

71,010 0.0690%
06-02Free

Director

19,676 0.0191%
06-02Free

Director

19,676 0.0191%
Change 5-day change 1-year change 3-year change Capi.($)
+3.57%+5.57%+98.83%+6.66% 3.3B
+3.16%+7.80%-6.70%+1.92% 44.45B
-0.60%+6.53%+319.89%+575.83% 36.04B
+2.35%+6.20%+4.56%+54.91% 30.7B
+6.59%+6.55%+14.68%-14.95% 28.59B
-4.75%-8.02%+5.99%+12.28% 23.01B
+0.90%+3.75% - - 14.82B
+6.02%+9.50%+58.76%+122.35% 13.52B
+2.70%+7.07%+10.90%+19.27% 12.98B
+1.95%+4.55%+95.99%+98.70% 12.56B
Average +2.16%+2.55%+66.99%+97.44% 22B
Weighted average by Cap. +1.93%+2.38%+70.17%+124.51%

Financials

2026 *2027 *
Net sales 73.19M 64.29M 59.24M 55.46M 104M 6.93B 106M 711M 275M 3.4B 275M 269M 11.82B 87.27M 76.67M 70.65M 66.14M 124M 8.27B 126M 848M 328M 4.06B 328M 321M 14.1B
Net income -465M -408M -376M -352M -660M -44.03B -671M -4.52B -1.75B -21.6B -1.74B -1.71B -75.08B -521M -457M -421M -394M -739M -49.31B -752M -5.06B -1.96B -24.2B -1.95B -1.91B -84.1B
Net Debt -855M -751M -692M -648M -1.21B -80.95B -1.23B -8.31B -3.22B -39.72B -3.21B -3.14B -138B -1.17B -1.03B -949M -888M -1.66B -111B -1.69B -11.39B -4.41B -54.47B -4.4B -4.3B -189B
Logo Beam Therapeutics Inc.
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).
Employees
522
Date Price Change Volume
26-06-24 US$34.10 +2.71% 228,470
26-06-23 US$33.20 -6.56% 3,604,536
26-06-22 US$35.53 +4.07% 2,603,285
26-06-18 US$34.14 +5.11% 3,509,471
26-06-17 US$32.48 +4.81% 2,174,739
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
33.20USD
Average target price
51.07USD
Spread / Average Target
+53.82%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BEAM Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!